Health Care · Services-Home Health Care Services

AHCO AdaptHealth Corp. SEC Filings & Insider Trading Activity 2026

company
CIK 1725255101 filings
Russell 2000

AHCO at a glance

AdaptHealth Corp. (AHCO, SEC CIK 1725255) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as September 11, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), AdaptHealth Corp. (AHCO) reported revenue of $3.2 billion (down 0.5% from FY2024) and a net loss of $70.8 million. Diluted EPS was -$0.52.
  • As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding AdaptHealth Corp. (AHCO) shares worth $308.2 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by WOLF DALE B on August 7, 2026 of 20,000 shares at $5.86 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$3.2B
−0.5% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
32 funds
$308.2M · −2 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Patient-centered healthcare-at-home solutions, including home medical equipment, medical supplies, and related services across four segments (Sleep, Respiratory, Diabetes, Wellness)
  • Newly emphasized: Deployment of artificial intelligence (AI), including generative AI, for improving patient and operational workflows with associated regulatory risks highlighted
  • Strategic shift: Increased focus on advanced technology platform integration and AI to enhance efficiency, compliance, and competitive positioning versus more manual competitors
  • Notable quantitative metric: Serviced approximately 4.3 million patients annually through 640 locations in 48 states; approximately 10,900 employees as of December 31, 2025
  • Distinctive fact: Outsourcing of about 4,400 full-time equivalent personnel for billing and administrative functions primarily in India and the Philippines

Risk Factors

  • Regulatory risk: 2026 CMS Final Rule bundling payment for CGMs and insulin pumps starting January 1, 2028, may disrupt AdaptHealth's product coverage and reimbursement
  • Macroeconomic risk: Inflation and rising interest rates could increase costs and interest expense on variable rate debt, impairing refinancing and cash flow
  • Supply chain risk: Dependence on few suppliers for patient service equipment exposes AdaptHealth to price hikes, tariffs, and supply disruptions impacting revenue
  • Competitive risk: Pharmacy benefit managers CVS Health and Optum, plus tech giants Amazon and Alphabet, entered HME market, threatening AdaptHealth’s referrals and revenue
  • Financial risk: Capitated agreements with managed care payors pose risk if patient care expenses exceed prepaid fixed payments, impacting earnings

Management Discussion & Analysis

  • Net revenue $3.24B in 2025, down 0.5% YoY from $3.26B in 2024, driven by $56.9M organic growth offset by $92.4M disposition decline
  • Operating margin 2.8% in 2025 vs 8.1% in 2024; net loss $(70.8M) vs net income $90.4M; goodwill impairment $128M in 2025 vs $13.1M prior year
  • Best performing segment Respiratory Health: revenue up 6.1% ($40M) to $691.2M; worst performing Wellness at Home: revenue down 9.8% ($63.1M) to $583.1M
  • Cost of net revenue increased 2.2% to $2.64B; G&A expenses up 6.4% to $382.3M; depreciation down 9.8% to $40.6M; capital allocation details not provided
  • Forward outlook highlights inflation risks impacting costs and demand; management leveraging purchasing power and technology for efficiencies; goodwill impairment risks remain

AI summary of the AHCO 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added supplier risk: Medline’s October 2026 field action removed all Medline Brand beds and related products from availability
  • Operational impact: Replacement beds may be unavailable timely or on similar terms, limiting patient-demand fulfillment
  • Regulatory risk: Medline cited potential electrical-system fire and entrapment hazards involving bed accessories
  • Financial risk: Field action may create significant unrecoverable costs for AdaptHealth
  • Supply-chain risk: Tariffs or excise taxes could increase patient-service equipment procurement costs

Management Discussion & Analysis

  • Revenue $745.6M, up 10.9% YoY from $672.4M, driven by capitated revenue arrangements at 14.8% vs 4.7%
  • Operating margin (20.9%) vs 6.5% YoY, including $184.8M goodwill impairment; Adjusted EBITDA margin 19.0% vs 21.7%
  • Best segment: Respiratory Health revenue $190.8M, up 7.8%, Adjusted EBITDA margin 29.5% vs 29.0%; worst: Wellness margin 9.3% vs 12.7%
  • Cash $80.7M; operating cash flow $156.6M, free cash flow $51.1M vs $66.8M YoY, reflecting $105.5M equipment purchases
  • Near-term outlook: liquidity sufficient for at least twelve months; inflation, supply-chain costs, cybersecurity remediation and capitated equipment spending remain headwinds

AI summary of the AHCO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • AdaptHealth reported financial results for the quarter ended September 30, 2026
  • Press release issued November 3, 2026 contains the substantive quarterly financial details

Item EX-99.1: Item EX-99.1

  • Q3 revenue $745.6M, up 10.9%, with organic growth 12.8% across all reportable segments
  • Adjusted EBITDA $141.9M, down 2.9%, with margin declining to 19.0% from 21.7%
Filed Sep 8, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Appointment of Mr. Currie as Chief Financial Officer, signaling a finance leadership transition
  • Executive change may affect financial reporting, capital allocation and investor communications

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Harriss Currie becomes CFO September 9, 2026, succeeding Jason Clemens after a one-day transition gap
  • $670,000 annual salary and 100% target bonus, with 2026 bonus prorated subject to continued employment

Item EX-99.1: Item EX-99.1

  • Harriss T. Currie appointed CFO effective September 9, 2026
  • Jason Clemens transitioning out through October 1, 2026
Filed Aug 4, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $740.3M, up 12.7%, with organic growth of 15.9% across all reportable segments
  • Adjusted EBITDA $132.0M, down 3.2%, with margin declining to 17.8% from 20.8%

Item 2.02: Results of Operations and Financial Condition

  • AdaptHealth reported financial results for the quarter ended June 30, 2026
  • Results announcement issued August 4, 2026, with detailed figures in Exhibit 99.1

AI summaries of AHCO 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for AHCO

Don't miss the next AHCO filing

  • Alerts as it files. A push when AHCO files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut AHCO, by share count.
  • Ask anything. An AI agent that reads every AHCO filing and answers with sources.

AHCO alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
CURRIE HARRISS TASep 9, 2026-
WOLF DALE BBuyAug 7, 2026$5.86
SAMET KENNETH ABuyAug 6, 2026$6.38
WOLF DALE BBuyAug 6, 2026$6.30
Schuster III Russell E.SellJul 1, 2026$10.44
Weaver Susan TAJun 24, 2026-
Lundberg Theodore B.AJun 24, 2026-
Coppens Bradley JAJun 24, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$3.2B$3.3B$3.2B
Operating Income-$598.4M$263.7M$90.9M
Net Income-$678.9M$90.4M-$70.8M
Op. Margin-18.7%8.1%2.8%
Net Margin-21.2%2.8%-2.2%
Balance Sheet
Total Assets-$4.5B$4.3B
Equity-$1.6B$1.5B
ROE-5.8%-4.7%
Per Share
EPS-$0.61$-0.52
Cash Flow
Operating CF-$541.8M$601.8M
CapEx$337.5M$306.1M$382.4M

Source: XBRL data in AdaptHealth Corp. (AHCO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate AHCO share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
AHCO shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202632$308.2M
Q2 202634$652.2M
Q1 202636$710.3M
Q4 202527$573.3M
Q3 202529$512.6M
Q2 202529$537.4M
Q1 202529$416.3M
Q4 202425$340.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 241 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

AHCO filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 3, 2026Analysis-
10-QNov 3, 2026Analysis
4Sep 11, 2026--
8-KSep 8, 2026Analysis-
4Aug 14, 2026--
4Aug 10, 2026--
4Aug 10, 2026--
8-KAug 4, 2026Analysis-
10-QAug 4, 2026Analysis
8-KJul 20, 2026Analysis-
8-KJul 7, 2026Analysis-
4Jul 6, 2026--
8-KJul 2, 2026Analysis-
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
8-KJun 22, 2026Analysis-
8-KJun 2, 2026Analysis
4May 29, 2026-
10-QMay 5, 2026Analysis

Related Health Care companies

All Health Care →

AHCO SEC filings: frequently asked questions

Which institutions hold AHCO stock?

As of September 30, 2026, the largest AdaptHealth Corp. (AHCO) holders among the 13F filers tracked by SignalX were BlackRock ($91.9 million), Dimensional Fund Advisors ($36.1 million), Vanguard Capital Management LLC ($27.4 million), State Street Corp ($26.9 million), AQR Capital Management ($23.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was AHCO's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), AdaptHealth Corp. (AHCO) reported revenue of $3.2 billion (down 0.5% from FY2024) and a net loss of $70.8 million. Diluted EPS was -$0.52. The figures come from the XBRL data in the 10-K.

What are the main risks in AHCO's latest 10-K?

In the 10-K filed February 24, 2026, AdaptHealth Corp. (AHCO) flagged: Regulatory risk: 2026 CMS Final Rule bundling payment for CGMs and insulin pumps starting January 1, 2028, may disrupt AdaptHealth's product coverage and reimbursement. Macroeconomic risk: Inflation and rising interest rates could increase costs and interest expense on variable rate debt, impairing refinancing and cash flow. (AI summary of the Risk Factors section.)

What did AHCO report in its latest 8-K?

AdaptHealth Corp. (AHCO) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). AdaptHealth reported financial results for the quarter ended September 30, 2026.

What are the latest AHCO SEC filings?

AdaptHealth Corp. (AHCO) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on September 11, 2026.

What is AHCO's SEC CIK number?

AdaptHealth Corp. (AHCO)'s SEC Central Index Key (CIK) is 1725255. EDGAR lists every AHCO filing under that number.

Ask anything about AHCO

The research agent reads AHCO's filings, financials, insider trades and 13F holders, then answers with sources.